Science

$Justin Stebbing: Botensilimab Plus Balstilimab in Patients With Relapsed/Refractory Metastatic Sarcomas$

Justin Stebbing/healthpost.in

Jan 29, 2025, 07:24

Justin Stebbing: Botensilimab Plus Balstilimab in Patients With Relapsed/Refractory Metastatic Sarcomas

Justin Stebbing, Professor of Biomedical Sciences at Anglia Ruskin University (ARU), shared his recent article on LinkedIn:

“Thanks to an amazing team and remarkable drugs, an Fc-enhanced CTLA-4 and anti-PD1, showing an impressive response rate and duration of response in heavily pre-treated sarcoma at Agenus, with special thanks to Robin Jones, Breelyn Wilky, Joseph Grossman and Steven O’Day.”

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.

Authors: Breelyn A. Wilky, et al.

$Justin Stebbing: Botensilimab Plus Balstilimab in Patients With Relapsed/Refractory Metastatic Sarcomas$

Agenus Anglia Ruskin University ARU Balstilimab botensilimab Breelyn A. Wilky Breelyn Wilky cancer CTLA-4 fight against cancer Global fight against cancer Joseph Grossman Justin Stebbing Metastatic Sarcomas OncoDaily Oncology Robin Jones Steven O'Day

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More

Senator John Fetterman Responds to Oncodaily on Pediatric Oncology Funding

Does Processed Meat Cause Cancer? Myths and Facts

Global Health Dialogues with Princess Dina Mired | Episode 1: Dr. Firas Al-Hawari

NEW PAPER ALERT: ESOPEC trial on Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer